Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension.
Jun Sung Moon, Kyung-Ah Han, Jae Myung Yu, Jong Chul Won, Jun Goo Kang, Soojin Park, Cheol-Young Park
Diabetes Res Clin Pract 236 113272
摘要
摘要
AIMS: This study evaluated the efficacy and safety of anagliptin added to metformin and empagliflozin in patients with type 2 diabetes (T2DM) inadequately controlled on dual therapy. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 3 trial, patients with T2DM (HbA1c 7.0-11.0 %) on metformin (≥1000 mg/day) and empagliflozin (25 mg/day) were randomized 1:1 to anagliptin (100 mg twice daily) or placebo for 24 weeks, followed by a 28-week open-label extension. The primary endpoint was HbA1c change from baseline to week 24. RESULTS: Of 200 randomized patients, 197 were analyzed (baseline HbA1c 7.76 %). At week 24, the least-squares mean HbA1c change was -0.83 % with anagliptin versus -0.03 % with placebo (difference -0.80 %; 95 % CI - 0.95 to - 0.64; P < 0.0001). The least-squares mean change in HOMA-β was + 10.45 versus -6.02 with placebo (between-group difference 16.46; P = 0.0003). Adverse events were similar between groups, with no severe hypoglycemia or deaths. CONCLUSIONS: In this first placebo-controlled trial evaluating DPP-4 inhibitor addition to maximally dosed empagliflozin (25 mg) plus metformin, anagliptin significantly improved glycemic control and β-cell function with a favorable safety profile, supporting this triple combination as an effective intensification strategy.
KM 提取结果
0 个 Figure · 0 个 KM 面板